Kazia Therapeutics Recommendation mean
What is the Recommendation mean of Kazia Therapeutics?
The Recommendation mean of Kazia Therapeutics Limited is 2.00
What is the definition of Recommendation mean?
Recommendation mean is the mean of analysts’ ratings of the stock ranging from 1.0 (strong buy) to 5.0 (strong sell).
Mean of recommendations is an average of ratings from different analysts but it should still be used with other research and investment metrics in order to make investment decisions. It is important to understand a firm's entire scale when assimilating ratings. Additionally, analyst recommendations on stocks owned by firms employing them may be seen as potentially biased.
Financial analysts are often employed by mutual and pension funds, hedge funds, securities firms, banks, investment banks, insurance companies, and other businesses, helping these companies or their clients make investment decisions. Financial analysts employed in commercial lending perform "balance sheet analysis," examining the audited financial statements and corollary data in order to assess lending risks. In a stock brokerage house or in an investment bank, they read company financial statements and analyze commodity prices, sales, costs, expenses, and tax rates in order to determine a company's value and project future earnings. In any of these various institutions, the analyst often meets with company officials to gain a better insight into a company's prospects and to determine the company's managerial effectiveness.
Usually, financial analysts study an entire industry, assessing current trends in business practices, products, and industry competition. They must keep abreast of new regulations or policies that may affect the industry, as well as monitor the economy to determine its effect on earnings.
Recommendation mean of companies in the Health Care sector on ASX compared to Kazia Therapeutics
What does Kazia Therapeutics do?
Kazia Therapeutics Limited, an oncology-focused biotechnology company, develops anti-cancer drugs. Its lead development candidate is GDC-0084, a small molecule, brain-penetrant inhibitor of the PI3K/Akt/mTor pathway, which is developed as a potential therapy for glioblastoma. The company is also developing Cantrixil, which is being developed for the treatment of ovarian cancer and is in hospitals across Australia and the United States under an Investigational New Drug application. Kazia Therapeutics Limited has collaboration agreements St Jude Childrens Hospital; Dana-Farber Cancer Institute; Alliance for Clinical Trials in Oncology; Memorial Sloan Kettering Cancer Centre; and University of Newcastle. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was founded in 1994 and is based in Sydney, Australia.
Companies with recommendation mean similar to Kazia Therapeutics
- Cabot Oil & Gas has Recommendation mean of 1.96
- Truist has Recommendation mean of 1.96
- Delta Air Lines has Recommendation mean of 1.96
- Discover Services has Recommendation mean of 1.96
- United Micro Electronics has Recommendation mean of 1.96
- Tapestry Inc has Recommendation mean of 1.97
- Kazia Therapeutics has Recommendation mean of 2.00
- Trip.com Ltd has Recommendation mean of 2.03
- Sherwin-Williams Co has Recommendation mean of 2.03
- Canadian Pacific Kansas City has Recommendation mean of 2.03
- Arista Networks Inc has Recommendation mean of 2.03
- Anheuser-Busch InBev SA/NV has Recommendation mean of 2.03
- Celanese Corp has Recommendation mean of 2.04